On July 17, 2024, SciSparc Ltd. announced signing a non-binding letter of intent for exclusive global licensing of a pain treatment, valued at approximately $6 million.
AI Assistant
SCISPARC LTD
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.